MyMD Pharmaceuticals reincorporates from New Jersey to Delaware

Q/C TECHNOLOGIES, INC.

Merger effective March 4, 2024; no change in company name, business, management, or fiscal year.
Stockholders approved reincorporation at 2023 annual meeting; common stock retains same CUSIP and symbol MYMD.
No exchange of stock certificates required; shares automatically convert on a 1:1 basis.
Rights of stockholders now governed by Delaware General Corporation Law.

item 1.01 item 3.03 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Q/C TECHNOLOGIES, INC. entered into Plan of Merger with MyMD New Jersey, MyMD Delaware (effective 2024-03-04).

Action: entry
Agreement: merger
Counterparty: MyMD New Jersey, MyMD Delaware
Effective: 2024-03-04

Exact text from the filing

MyMD Pharmaceuticals, Inc., a New Jersey corporation (“MyMD New Jersey” or, prior to the Reincorporation (as defined below), the “Company”) merged with and into its wholly-owned subsidiary, MyMD Pharmaceuticals, Inc., a Delaware corporation (“MyMD Delaware” or, following the Reincorporation, the “Company”), with MyMD Delaware being the surviving corporation, pursuant to that certain Agreement and Plan of Merger, dated as of March 4, 2024, by and between MyMD New Jersey and MyMD Delaware (the “Plan of Merger”)

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

Q/C TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-009220

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.